Biotech News

Absci to Participate in Upcoming Investor Conferences

Absci Corporation (ABSI)Absci Corporation2026-05-20 12:00 ESTCompany update

VANCOUVER, Wash. and NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the company will be participating in the following upcoming investor

Related news

ABSIAbsci Corporation2026-04-08 12:00 EST

Absci to Participate in the 25th Annual Needham Virtual Healthcare Conference

ABSIAbsci Corporation2025-12-16 13:00 EST

Absci to Participate in the 44th Annual J.P. Morgan Healthcare Conference

View all latest news

Absci Corporation

AI-Enabled Biologic Design Absci combines generative artificial intelligence with high-throughput synthetic biology to design and validate novel biologics. Its integrated platform repeatedly feeds laboratory results back into computational models. ABS-201 ABS-201 is a long-acting antibody against the prolactin receptor. Its...

Recent company news

ABSIAbsci Corporation2026-07-14 20:05 EST

Absci to Report Business Updates and Second Quarter 2026 Financial and Operating Results on August 11, 2026

ABSIAbsci Corporation2026-06-24 10:35 EST

Absci Announces Pricing of $100 Million Underwritten Offering with Leading Strategic and Financial Investors

ABSIAbsci Corporation2026-06-24 10:30 EST

Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR)

ABSIAbsci Corporation2026-05-20 12:00 EST

Absci to Participate in Upcoming Investor Conferences

ABSIAbsci Corporation2026-05-07 20:06 EST

Absci Reports Business Updates and First Quarter 2026 Financial and Operating Results

Stock data

Close: 8.30 USD
Market cap: 990M USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States